The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure

Cancer Letters

Volumn 183, Issue 1, 2002, Pages 69-77

  Zhao, Jianhua ^a   Wang, Mijuan ^b   Chen, Jie ^b   Luo, Aiping ^a   Wang, Xiuqin ^a   Wu, Min ^a   Yin, Dali ^b   Liu, Zhihua ^a  

^a CANCER HOSPITAL   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

HDM2; Nonpeptidic small molecule HDM2 inhibitor; p53

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN DERIVATIVE; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; SYC 10; SYC 11; SYC 12; SYC 13; SYC 14; SYC 15; SYC 16; SYC 17; SYC 18; SYC 19; SYC 20; SYC 21; SYC 22; SYC 23; SYC 24; SYC 25; SYC 26; SYC 27; SYC 28; SYC 29; SYC 30; SYC 31; SYC 32; SYC 37; SYC 40; SYC 7; SYC 8; SYC 9; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BIOASSAY; CANCER CELL CULTURE; CELL ASSAY; COMPLEX FORMATION; COMPUTER AIDED DESIGN; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, SMALL CELL; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HELA CELLS; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037044103     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00084-8     Document Type: Article

References (18)

1. p53, the cellular gatekeeper for growth and division
2. The p53-mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?
3. Mdm2: Keeping p53 under control
4. Mdm2 promotes the rapid degradation of p53
5. MDM2-arbiter of p53's destruction
6. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
7. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm2
8. P53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
9. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines
10. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
11. Identification of novel mdm2 binding peptides by phage display
12. Chemosensitivity testing of fresh human gastric cancer with highly purified tumor cells using the MTT assay
13. P53 mutation in human cancer
14. P53 and human cancers
15. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
16. Mdm2 expression is induced by wild type p53 activity
17. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
18. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target